rais target post result mark modestli better
natx growth strong on-going calcimimet tailwind solid
oper guidanc addit see attract opportun around
home expect on-going efforts/invest
advanc integr care aid strateg posit head wind remain
 calcimimet y/i labor cost execut solid cash
flow robust applaud capit effici focu maintain hold
rate rais pt ep vs
result net revenu ahead better
expect natx growth vs strhe off-set slightli
lower revenu per treatment vs strhe top line
coupl slightli better ebit margin modestli higher patient
care cost revenu vs strhe larg off-set strong
adjust ebit vs strhe compani also provid
addit guidanc detail rais prior adjust ep guidanc
midpoint vs delta
tie larg calcimimet expect oi lower
impact manag guid net revenu vs prior
strhe oper incom margin vs prior
strhe view guidanc solid oper guidanc
larg unchang compani also expect natx strhe
free cash flow
shift dialysi volum home esrd medicar advantag
coverag see attract opportun view well
posit expect compani continu invest alreadi attract
home platform educ remot monitor predict model
expand nephrolog allianc nephrologist work execut
goal doubl digit pd growth compani biggest pd
growth year front work anticip expand
esrd coverag invest data/predict analyt patient
engag drive deeper integr help better identifi ckd patient
high risk esrd creat mutual benefici payment model
potenti increment opportun around difficult size robust
home platform grow predict analyt capabl sizabl current
popul today view well-posit
tr target
ebitda adjust nci equiti incom
posit oi addit tidbit busi saw posit
oper incom despit fx loss segment finish year oi
ex goodwil impair inclus fx head wind expect compani continu
strateg deploy capit open de novo attract market maintain disciplin around
invest paramet remain bullish growth prospect segment like increment
diversif continu expect becom meaning contributor time result
includ profit calcimimet drive ebit margin revenue/tx
sequenti calcimimet impact revenu per tx ex calcimimet
full-year rev/tx ex calcimimet impact high-end guidanc rang
commerci mix y/i chang meaning impact revenue/tx
trend robust guidanc updat adjust estim cash flow trend
strong adjust cffo crush estim
addit compani expect capital-expenditure rang year
 vs strhe cash flow favor impact tie
two factor expect recur dso improv unusu low cash tax
dso improv day sequenti day compani repurchas share
averag cost repurchas addit share
averag cost compani exit year leverag low end
compani target rang ex-calcimimet benefit would toward high end
expect benefit lower interest cost tie expect near term repric term
loan updat estimates/tweak pace reflect updat guidanc
adjust ebitda adjust ep
maintain hold rais price target
page
revenu
revenu
revenu
revenu
revenu
amort net tax
page
base denver co davita inc lead provid dialysi servic unit state
intern patient suffer chronic kidney failur end stage renal diseas esrd
continu like core dialysi busi acknowledg potenti opportun tie
integr care longer term view near term fundament mix enthusiasm
expect improv capit effici somewhat off-set industri pressur labor ballot
initi slow organ volum trend rate share hold
valuat risk
price target base trade adjust ep slight discount industri
peer freseniu medic fm view appropri given less product geograph
diversif recent sluggish organ volum trend
risk rate price target upsid risk includ better expect reimburs
oper perform downsid risk includ wors expect reimburs pressur
slow organ trend
david macdonald herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express
specif recommend report
